Celecoxib for Rheumatoid Arthritis

This Cochrane systematic review assesses the benefits and harms of celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), in people with rheumatoid arthritis. This systematic review included 8 randomized control trials with durations of 4 to 24 weeks, published between 1998 and 2014, that involved a total of 3,988 adults (mean age = 54 years), most of whom were women (73%), and found that celecoxib may improve clinical symptoms, alleviate pain, and contribute to little or no difference in physical function compared with placebo.